COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,441 Articles (22,835 medRxiv, 8,606 bioRxiv)

Most recent first Previous |  Page 2130: Articles 21291-21300  | Next

U-shaped-aggressiveness of SARS-CoV-2: Period between onset of nonspecific-specific symptoms for COVID-19. A population-based cohort study
Morgenstern-Kaplan, D., Buitano-Tang, B., Martinez-Gil, M., Zaldivar-Perez Pavon, A., Talavera, J. O.
10.1101/2020.10.28.20221697 — Posted: 2020-11-03
A Multi-Factor Risk Model for Severe Covid-19 for Vaccine Prioritization and Monitoring Based on a 15 Million Medicare Cohort
Experton, B., Tetteh, H., Lurie, N., Walker, P., Carroll, C., Elena, A., Hein, C., Schwendiman, B., Burrow, C.
10.1101/2020.10.28.20219816 — Posted: 2020-11-03 Discussion: Onsite
Frequency and profile of objective cognitive deficits in hospitalized patients recovering from COVID-19
Jaywant, A., Vanderlind, W. M., Alexopoulos, G. S., Fridman, C. B., Perlis, R. H., Gunning, F. M.
10.1101/2020.10.28.20221887 — Posted: 2020-11-03
They're Dying in the Suburbs: COVID-19 Cases and Deaths by Geography in Louisiana (USA)
Schnake-Mahl, A., Bilal, U.
10.1101/2020.10.28.20221341 — Posted: 2020-11-03
Performance of EasyBreath(R) Decathlon Snorkeling mask for Delivering Continuous Positive Airway Pressure
Noto, A., Crimi, C., Cortegiani, A., Giardina, M., Benedetto, F., Princi, P., Carlucci, A., Appendini, L., Gregoretti, C.
10.1101/2020.10.28.20221317 — Posted: 2020-11-03
Effect of control measure on the development of new COVID-19 cases through SIR model simulation
Liu, F., Lee, C.
10.1101/2020.10.27.20220590 — Posted: 2020-11-03
Real-life performances of a novel antigen detection test on nasopharyngeal specimens for SARS-CoV-2 infection diagnosis: a prospective study
Courtellemont, L., Guinard, j., Guillaume, C., Giache, S., Rzepecki, V., Seve, A., Gubavu, C., Baud, K., Doize, H., Le Helloco, C., Lebegue, C., Tay, E. A., Cassuto, G., Pialoux, G., Hocqueloux, L., prazuck, t.
10.1101/2020.10.28.20220657 — Posted: 2020-11-03
Liquid chalk is an antiseptic against SARS-CoV-2 and influenza A respiratory viruses
McAuley, J. L., Deerain, J. M., Hammersla, W., Aktepe, T. E., Purcell, D. J. F., Mackenzie, J.
10.1101/2020.11.02.364661 — Posted: 2020-11-02
Ivermectin reduces coronavirus infection in vivo: a mouse experimental model
Arevalo, A. P., Pagotto, R., Porfido, J., Daghero, H., Segovia, M., Yamasaki, K., Varela, B., Hill, M., Verdes, J. M., Duhalde Vega, M., Bollati-Fogolin, M., Crispo, M.
10.1101/2020.11.02.363242 — Posted: 2020-11-02
Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection
Zuo, J., Dowell, A., Pearce, H., Verma, K., Long, H., Begum, J., Aiano, F., Amin-Chowdhury, Z., Hallis, B., Stapley, L., Borrow, R., Linley, E., Ahmad, S., Parker, B., Horsley, A., Amirthalingam, G., Brown, K., Ramsay, M. E., Ladhani, S., Moss, P.
10.1101/2020.11.01.362319 — Posted: 2020-11-02 Discussion: Onsite | Offsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).